IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

For: Novel cytokine receptors and nucleic acids encoding the same	Customer No. 35489
Filed: November 3, 2003) Attorney's Docket No. GNE-0304 R1C1
Application Serial No. 10/700,992) Confirmation No: 4868
Audrey Goddard, et al.) Art Unit: 1646
In re application of:) Examiner: Elizabeth Kemmerer

FILED BY EFS ON JANUARY 13, 2010

Petition for Revival of a Patent Application Under 37 CFR §1.137(b)

MAIL STOP PETITION

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Dear Sir or Madam:

Applicants hereby petition for revival of the above-captioned patent application under 37 C.F.R. §1.137(b). Authorization to charge the official fee under 37 C.F.R. § 1.17(m) for this Petition is given in the accompanying transmittal letter. If needed, authorization for any additional official fees under 37 C.F.R. § 1.17(t) for amending a priority claim is also provided.

In the accompanying documents, Applicants seek to amend the priority claim in Appln. Serial No. 11/697,201 to reflect additional priority data determined by Applicants. See, e.g. Petition to Amend Priority Under 37 C.F.R. § 1.78(a)(3) and 1.78(a)(6), filed in the 11/697,201 application. In amending the priority claim in Appln. Serial No. 11/697,201, Applicants noted that the above-captioned application, which is in the chain of priority for Appln. Serial No. 11/697,201, contained a claim for priority that may require amendment. Therefore, by way of this Petition, Applicants seek to revive the above-captioned application solely for the purpose of amending the priority claim to reflect the data submitted in the Amendment filed herewith and attached hereto as Exhibit A (the "Amendment"). Applicants note that the Amendment merely corrects the form of the priority claim in the above-captioned application to comply with the requirements of 37 C.F.R. § 1.78(a)(2)(ii) and (a)(5)(ii).

In light of the above, revival of the above-captioned application is respectfully requested solely for the purpose of entering the Amendment. Further, Applicants respectfully request that the above-captioned application be expressly abandoned upon entry of the Amendment.

Applicants respectfully submit that the entire delay between the date the claim was due under 37 CFR \$1.78(a)(2)(ii) and 37 CFR \$1.78(a)(5)(ii), and the date the claim was filed was unintentional.

In summary, Applicants hereby petition for revival of the above-identified application and correction of the priority claim as indicated in the Amendment of Exhibit A.

-2-

REMARKS

The Commissioner is authorized to charge any applicable fees for this Petition to Deposit Account No. 50-2387 (24126.182), referencing Attorney's Docket No. GNE-0304 R1C1; (P3121R1C1). Such payment is believed to be in the amount of \$1,620 for the petition fee required by 37 C.F.R. §1.17(m).

Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Arnold & Porter LLP

Date: January 13, 2010 By: /Jeffery P. Bernhardt/

Jeffery P. Bernhardt (Reg. No. 54,997)

ARNOLD & PORTER LLP 555 Twelfth Street, NW Washington, D.C. 20004-1206 Telephone: +1 202.942.5000 Facsimile: +1 202.942.5999 Direct Line: +1 415 356-3027

Exhibit A

Amendments to the Specification

Please replace the paragraph beginning at page 1, line 2, with the following paragraph in column 1. lines 4-12 as follows:

--This application is a continuation application claiming priority under 35 U.S.C. § 120 of U.S. Application Serial No. 09/964,994 filed September 26, 2001, now U.S. Patent No. 6,740.520, the entire disclosure of which is hereby expressly incorporated by reference. The 09/941,992 application claims priority under 35 U.S.C. § 120 and is a continuation-in-part of PCT Application No. PCT/US01/06666 filed March 1, 2001. PCT Application No. PCT/US01/06666 claims priority under 35 U.S.C. § 119(e) to U.S. provisional Application Serial No. 60/191.015 filed on March 21, 2000,--